In 2031, GlobalData's sales and forecast tool predicts obesity drugs to collectively generate $172.6bn, a rise of 139% from the $72.2bn forecast for 2026
[5] Hence SAM synthetase is fast becoming a drug target, in particular for the following diseases: depression, dementia, vacuolar myelopathy, liver injury, migraine, osteoarthritis, and as a potential cancer chemopreventive agent
Also, stromal cells and fibroblasts are the main source of HGF production
Histograms were created for statistically significant mean metal intensity (MMI) expressions using FlowJo
Met-204 and Tyr-205 are together important for binding GLP-1 receptor agonists but not their N-terminally truncated analogues
Peptide chemists will use non-natural amino acids, backbone modifications, and cyclization to increase stability and half-life from minutes to hours or days, which cuts dosing frequency